ASH 2021 Conference Coverage on VuMedi

 

MDS and MPN
06:20

ASH 2021 Conference Coverage on VuMedi

Retrospective Head-to-Head Comparison Between Pacritinib and Ruxolitinib in Patients With Myelofibrosis and Moderate-to-Severe Thrombocytopenia

FEATURING John Mascarenhas
  • 115 views
  • March 2, 2022
07:13

ASH 2021 Conference Coverage on VuMedi

FDA Approval and Safety Analysis of Pacritinib in Patients With Myelofibrosis and Severe Thrombocytopenia

FEATURING John Mascarenhas
  • 156 views
  • March 2, 2022
10:26

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on a Pooled Analysis of the COMFORT-I & II Studies: Does Early Intervention In Myelofibrosis Impact Outcomes?

FEATURING Srdan Verstovsek
  • 311 views
  • February 14, 2022
06:04

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Clinical and Pathological Characteristics of Hypocellular MDS: A Single-Center Retrospective Study

FEATURING Kunhwa Kim
  • 152 views
  • January 6, 2022
05:14

ASH 2021 Conference Coverage on VuMedi

ASH 2021 NGS Evaluation of the EQoL-MDS Trial: Preliminary Analysis of Eltrombopag for Thrombocytopenia of LR-MDS

FEATURING Esther Oliva
  • 118 views
  • December 23, 2021
  • 1
11:04

ASH 2021 Conference Coverage on VuMedi

ASH 2021: Evaluation of IWG 2006 Response Criteria in Patients with HR-MDS Treated With HMA Monotherapy in the 1L Setting

FEATURING Jan Bewersdorf
  • 123 views
  • December 23, 2021
  • 1
06:52

ASH 2021 Conference Coverage on VuMedi

ASH 2021: A Phase 3 Study of Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera

FEATURING Srdan Verstovsek
  • 97 views
  • December 22, 2021
11:17

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on the Management of Polycythemia Vera

FEATURING Andrew Kuykendall
  • 39 views
  • December 22, 2021
04:45

ASH 2021 Conference Coverage on VuMedi

ASH 2021 on LR-MDS: Factors Predicting Progression to HR-MDS and AML in Patients with Very Low and LR-MDS According to the R-IPSS Criteria

FEATURING Akriti Jain
  • 98 views
  • December 22, 2021
08:59

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on the Outcomes of Therapy-Related Myeloid Neoplasms With Venetoclax-Based Therapy

FEATURING Mithun Shah
  • 12 views
  • December 22, 2021
08:12

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Efficacy and Safety of Parsaclisib+Ruxolitinib Combination in Patients With Myelofibrosis

FEATURING Abdulraheem Yacoub
  • 13 views
  • December 22, 2021
08:30

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Presentation on Tagraxofusp, a First-in-Class CD123-Targeted Therapy, in Patients With R/R MF

FEATURING Abdulraheem Yacoub
  • 70 views
  • December 22, 2021
05:32

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Highlights on Ruxolitinib + Parsaclisib for JAK-/PI3K-Inhibitor Treatment-Naïve Myelofibrosis

FEATURING Abdulraheem Yacoub
  • 67 views
  • December 22, 2021
08:15

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Highlights in MPN

FEATURING Prithviraj Bose
  • 249 views
  • December 22, 2021
15:25

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Clinical and Translational Data From the Ongoing MANIFEST Trial: Pelabresib Monotherapy for Myelofibrosis

FEATURING Marina Kremyanskaya
  • 88 views
  • December 20, 2021
10:43

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Final Results of a Phase 2 Study of Sotatercept for Anemia of MPN-Associated Myelofibrosis

FEATURING Prithviraj Bose
  • 98 views
  • December 20, 2021
05:06

ASH 2021 Conference Coverage on VuMedi

Positioning Fedratinib in the Treatment Strategy of Myelofibrosis

FEATURING Francesco Passamonti
  • 141 views
  • December 20, 2021
  • 1
13:17

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Molecular Responses in Treatment-Naïve HR-MDS Patients Treated With Venetoclax + Azacitidine

FEATURING Jacqueline Garcia
  • 75 views
  • December 17, 2021
12:03

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Highlights on Efficacy and Safety of Sabatolimab for Patients With HR-MDS or AML

FEATURING Andrew Brunner
  • 72 views
  • December 17, 2021
06:27

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on the Phase 2 Study of Bomedemstat (IMG-7289) In Patients with Advanced MF

FEATURING Harinder Gill
  • 477 views
  • December 17, 2021
  • 5
07:56

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with MF

FEATURING John Mascarenhas
  • 52 views
  • December 17, 2021
10:27

Richard T. Silver

Splenomegaly in Polycythemia Vera: Clinical Significance and Relation to Myelofibrosis and Survival

  • 329 views
  • December 16, 2021
  • 1
10:44

Aaron Gerds

A Real-World Evaluation of the Association Between Elevated Blood Counts and Thrombotic Events in PV: REVEAL Study Data Analysis

  • 1,052 views
  • December 16, 2021
  • 1
15:40

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on the “AAA” Risk Model for Essential Thrombocythemia: Age, ANC, and ALC

FEATURING Ayalew Tefferi
  • 437 views
  • December 16, 2021
  • 1
05:15

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on Clinical Outcomes at 3 and 6 Months of Fedratinib Therapy Following Prior Ruxolitinib Failure: Real-World Assessment of Spleen, Symptoms, and Hematologic Response

FEATURING John Mascarenhas
  • 617 views
  • December 15, 2021
  • 2